Update information
October 2019: Information has been added to recommendations in section 1.3 on PPI and H2RA licensing for use in children. Recommendation 1.3.7 has been amended to clarify when metoclopramide, domperidone or erythromycin can be offered.
Minor changes since publication
March 2025: We updated links following publication of NICE's guideline on overweight and obesity management.
March 2024: We updated links to our guidance on bacterial meningitis and meningococcal disease following the launch of NICE's guideline on meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management.
May 2021: In recommendation 1.3.7, we highlighted the MHRA drug safety updates about the risk of infantile hypertrophic pyloric stenosis with erythromycin, cardiac risks with erythromycin and potential drug interaction of erythromycin with rivaroxaban.
ISBN: 978-1-4731-0931-5